

## **François AUDENET**

---

**François AUDENET, M.D.**

**Urologist**

**Hôpital Européen Georges Pompidou**

**Université Paris Descartes**

**38 years old**

**E-mail:** francois.audene<at>aphp.fr

## **CURRICULUM VITAE (updated Oct. 2019)**

### **EDUCATION**

2001-2006 Medical school at Faculté de Médecine de Rouen

2011 Research Master's Degree in Surgical Sciences – Option Oncology

2012 Medical Thesis (MD), Sorbonne Université, Paris

2013 Board certified in Andrology

2014 Board certified in Urology

2014 Fellow of the European Board of Urology (FEBU)

### **MEDICAL TRAINING**

2006-2012 Residency at Greater Paris University Hospitals, General Surgery and Urology, Paris, France

2012-2013 Urologic Oncology and Minimally Invasive Surgery Fellowship at Institut Mutualiste Montsouris, Department of Urology, Dr Cathelineau, Paris, France

2013-2016 Assistant Professor (Chef de Clinique – Assistant des Hôpitaux), Department of Urology, Pr. Méjean, Hôpital Européen Georges Pompidou (HEGP), Université Paris Descartes, Paris, France

2019-today Associate Professor (MCU-PH), Department of Urology, Pr. Méjean, Hôpital Européen Georges Pompidou (HEGP), Université Paris Descartes, Paris, France

### **RESEARCH ACTIVITIES**

2011 Research Fellowship, GRC N°5 Sorbonne Université, Pr. CUSSENOT, Paris, France; "Role of germline single nucleotide polymorphisms as risk factors of renal cell carcinoma"

2016-2018 Research Fellowship, Center for Molecular Oncology, Human Oncology and Pathogenesis Program, David B. SOLIT, Memorial Sloan Kettering Cancer Center, New York, USA

2018-today PhD student, Centre de Recherche des Cordeliers, INSERM UMRS 1138, Département Génome et Cancer, Pr. Pierre LAURENT-PUIG, Paris, France

## AWARDS

2011 Gold Medal in Surgery (Médaille d'Or de l'Internat, section Chirurgie, Assistance Publique – Hôpitaux de Paris (AP-HP))

2012 Le Dentu-Renon Prize from the National Surgical Academy (Académie Nationale de Chirurgie)

2013 1st Prize of Urology from the National Academy of Medicine (Prix d'Urologie de l'Académie Nationale de Médecine)

2013 EUROCANCER Thesis Prize

## PUBLICATIONS

1. Nguyen K, Eltz S, Drouin SJ, Comperat E, **Audenet F**, Renard-Penna R, Bitker M-O, Chartier-Kastler E, Richard F, Cussenot O, Rouprêt M. Oncologic outcome after radical prostatectomy in men with PSA values above 20 ng/ml: a monocentric experience. *World J Urol.* 2009 May 23;27(5):653–8.
2. **Audenet F**, Rouprêt M, Méjean A. Cancer du rein et thérapies ciblées : controverses sur les prises en charge thérapeutiques. *Prog Urol.* 2009 Oct;19(9):596–605.
3. **Audenet F**, Rouprêt M. Les torsions du cordon spermatique : aspects du diagnostic clinique et principes thérapeutiques. *Prog Urol.* 2010 Nov;20(11):810–4.
4. **Audenet F**, Cornu J-N, Maillet M, Lukacs B, Sèbe P, Peyrat L, Tligui M, Traxer O, Haab F. Évaluation de la pratique de la chirurgie ambulatoire en urologie: expérience d'un centre. *Prog Urol.* 2011 May;21(5):354–9.
5. Rouprêt M, **Audenet F**. Controverses, débats et défis: comment construire l'urologie de demain? *Prog Urol.* 2011 May;21 Suppl 3:S73–4.
6. **Audenet F**, Rouprêt M. Controverses dans le cancer de la prostate localisé: épidémiologie, dépistage et stadification. *Prog Urol.* 2011 May;21 Suppl 3:S75–9.
7. **Audenet F**, Rouprêt M. Prise en charge thérapeutique des cancers de la prostate à haut risque: actualités et perspectives. *Prog Urol.* 2011 May;21 Suppl 3:S80–3.
8. **Audenet F**, Rouprêt M. Innovations chirurgicales et stratégies thérapeutiques dans les carcinomes à cellules rénales. *Prog Urol.* 2011 May;21 Suppl 3:S84–7.
9. **Audenet F**, Rouprêt M, Perrin P, La Taille de A. Comment sélectionner au mieux les candidats aux biopsies de prostate ? Rôle des outils traditionnels et apport des nouveaux marqueurs du cancer de la prostate. *Prog Urol.* 2011 May;21 Suppl 3:S88–92.
10. **Audenet F**, Rouprêt M, Mozer P. Évolution de l'imagerie moderne et développement des biopsies de prostate ciblées pour le diagnostic du cancer de la prostate. *Prog Urol.* 2011 May;21 Suppl 3:S93–5.
11. **Audenet F**, Rouprêt M, Tombal B. Innovations dans le traitement hormonal du cancer de la prostate localement avancé et/ou métastatique. *Prog Urol.* 2011 May;21 Suppl 3:S96–101.
12. **Audenet F**, Comperat E, Serigne E, Drouin SJ, Richard F, Cussenot O, Bitker M-O, Rouprêt M. Oncologic control obtained after radical prostatectomy in men with a pathological Gleason score 8: a single-center experience. *Urol Oncol.* 2011 Nov;29(6):602–7.
13. **Audenet F**, Traxer O, Yates DR, Cussenot O, Rouprêt M. Potential role of photodynamic techniques combined with new generation flexible ureterorenoscopes and molecular markers for the management of urothelial carcinoma of the upper urinary tract. *BJU Int.* 2012 Feb;109(4):608–13–discussion613–4.
14. **Audenet F**, Serigne E, Drouin SJ, Comperat E, Cussenot O, Bitker M-O, Rouprêt M. Persistently elevated prostate-specific antigen at six weeks after radical prostatectomy helps in early identification of patients who are likely to recur. *World J Urol.* 2012 Apr;30(2):239–44.
15. **Audenet F**, Lejay V, Méjean A, La Taille de A, Abbou C-C, Lebret T, Botto H, Bitker MO, Rouprêt M. Les décisions sont-elles homogènes en réunion de concertation pluridisciplinaire (RCP) en onco-urologie ? Comparaison des choix thérapeutiques dans quatre RCP parisiennes. *Prog Urol.* 2012 Jun;22(7):433–7.
16. **Audenet F**, Yates DR, Cancel-Tassin G, Cussenot O, Rouprêt M. Genetic pathways involved in carcinogenesis of clear cell renal cell carcinoma: genomics towards personalized medicine. *BJU Int.* 2012 Jun;109(12):1864–70.
17. **Audenet F**, Colin P, Yates DR, Ouzzane A, Pignot G, Long J-A, Soulié M, Phe V, Bensadoun H, Guy L, Ruffion A, Valeri A, Cormier L, Droupy S, La Taille De A, Saint F, Faïs P-O, Houlgatte A, Cussenot O, Rouprêt M, for the French Collaborative National Database on UUT-UC. A proportion of hereditary upper urinary tract urothelial carcinomas are

misclassified as sporadic according to a multi-institutional database analysis: proposal of patient-specific risk identification tool. *BJU Int.* 2012 Jun 15;110(11b):E583–9.

18. Colin P, Ouzzane A, Yates DR, **Audenet F**, Pignot G, Arvin-Berod A, de Treigny OM, Laurent G, Valeri A, Jacques I, Saint F, Gardic S, Gres P, Rozet F, Neuzillet Y, Ruffion A, Rouprêt M. Influence of Positive Surgical Margin Status After Radical Nephroureterectomy on Upper Urinary Tract Urothelial Carcinoma Survival. *Ann Surg Oncol.* 2012 Jul 28;19(11):3613–20.

19. **Audenet F**, Méjean A, Chartier-Kastler E, Rouprêt M. Adrenal tumours are more predominant in females regardless of their histological subtype: a review. *World J Urol.* 2013 Jan 9;31(5):1037–43.

20. **Audenet F**, Traxer O, Bensalah K, Rouprêt M. Upper urinary tract instillations in the treatment of urothelial carcinomas: a review of technical constraints and outcomes. *World J Urol.* 2013 Feb;31(1):45–52.

21. Xylinas E, Colin P, **Audenet F**, Phe V, Cormier L, Cussenot O, Houlgatte A, Karsenty G, Bruyère F, Polguer T, Ruffion A, Valeri A, Rozet F, Long J-A, Zerbib M, Rouprêt M. Intravesical recurrence after radical nephroureterectomy for upper tract urothelial carcinomas: predictors and impact on subsequent oncological outcomes from a national multicenter study. *World J Urol.* 2013 Feb;31(1):61–8.

22. Nison L, Rouprêt M, Bozzini G, Ouzzane A, **Audenet F**, Pignot G, Ruffion A, Cornu J-N, Hurel S, Valeri A, Roumigué M, Polguer T, Hoarau N, Mériçot de Treigny O, Xylinas E, Matte A, Droupy S, Faïs P-O, Descazeaud A, Colin P, MD for the French Collaborative National Database on UUT-UC. The oncologic impact of a delay between diagnosis and radical nephroureterectomy due to diagnostic ureteroscopy in upper urinary tract urothelial carcinomas: results from a large collaborative database. *World J Urol.* 2013 Feb;31(1):69–76.

23. Bozzini G, Nison L, Colin P, Ouzzane A, Yates DR, **Audenet F**, Pignot G, Arvin-Berod A, Merigot O, Guy L, Irani J, Saint F, Gardic S, Gres P, Rozet F, Neuzillet Y, Ruffion A, Rouprêt M. Influence of preoperative hydronephrosis on the outcome of urothelial carcinoma of the upper urinary tract after nephroureterectomy: the results from a multi-institutional French cohort. *World J Urol.* 2013 Feb;31(1):83–91.

24. Ouzzane A, Colin P, Ghoneim TP, Zerbib M, La Taille De A, **Audenet F**, Saint F, Hoarau N, Adam E, Azemar MD, Bensadoun H, Cormier L, Cussenot O, Houlgatte A, Karsenty G, Maurin C, Nouhaud FX, Phe V, Polguer T, Roumigué M, Ruffion A, Rouprêt M. The impact of lymph node status and features on oncological outcomes in urothelial carcinoma of the upper urinary tract (UTUC) treated by nephroureterectomy. *World J Urol.* 2013 Feb;31(1):189–97.

25. **Audenet F**, Yates DR, Cussenot O, Rouprêt M. The role of chemotherapy in the treatment of urothelial cell carcinoma of the upper urinary tract (UUT-UCC). *Urol Oncol.* 2013 May;31(4):407–13.

26. Rozet F, **Audenet F**, Sanchez-Salas R, Galiano M, Barret E, Cathelineau X. Accurate patient selection and multimodal treatment offer the best therapeutic option in high-risk prostate cancer. *Expert Rev Anticancer Ther.* 2013 Jul;13(7):811–8.

27. Murez T, Basset V, **Audenet F**, Lebret T, Branchereau J. Régulation hormonale qualitative et quantitative dans le cancer de la prostate résistant à la castration. *Prog Urol.* 2013 Oct;23 Suppl 1:S1–8.

28. **Audenet F**, Murez T, Ripert T, Villers A, Neuzillet Y. Inhibiteurs de CYP17A1 dans le cancer de la prostate: mécanismes d'action indépendants de la voie de signalisation androgénique. *Prog Urol.* 2013 Oct;23 Suppl 1:S9–15.

29. Ploussard G, Staerman F, Pierrevelcin J, Saad R, Beauval J-B, Rouprêt M, **Audenet F**, Peyromaure M, Barry Delongchamps N, Vincendeau S, Fardoun T, Rigaud J, Villers A, Bastide C, Soulié M, Salomon L. Predictive Factors of Oncologic Outcomes in Patients Who do not Achieve Undetectable Prostate Specific Antigen after Radical Prostatectomy. *J Urol.* 2013 Nov;190(5):1750–6.

30. Pignot G, Colin P, Zerbib M, **Audenet F**, Soulié M, Hurel S, Delage F, Irani J, Descazeaud A, Droupy S, Rozet F, Phe V, Ruffion A, Long J-A, Crouzet S, Houlgatte A, Bigot P, Guy L, Faïs P-O, Rouprêt M, French Collaborative National Database on UUT-UC. Influence of previous or synchronous bladder cancer on oncologic outcomes after radical nephroureterectomy for upper urinary tract urothelial carcinoma. *Urol Oncol.* 2014 Jan;32(1):23.e1–8.

31. **Audenet F**, Cancel-Tassin G, Bigot P, Audouin M, Gaffory C, Ondet V, Thibault F, Auribault K, Gazut S, Benhabiles N, Azzouzi AR, Méjean A, Rouprêt M, Cussenot O. Germline Genetic Variations at 11q13 and 12p11 Locus Modulate Age at Onset for Renal Cell Carcinoma. *J Urol.* 2014 Feb;191(2):487–92.

32. Bigot P, Hétet J-F, Bernhard J-C, Fardoun T, **Audenet F**, Xylinas E, Ploussard G, Pignot G, Bessede T, Ouzaid I, Robine E, Brureau L, Mériçot de Treigny O, Maurin C, Long J-A, Rouffilange J, Hoarau N, Lebdaï S, Rouprêt M, Bastien L, Neuzillet Y, Mongiat-Artus P, Verhoest G, Zerbib M, Ravery V, Rigaud J, Bellec L, Baumert H, Chautard D, Bensalah K, Escudier B, Paparel P, Grenier N, Rioux-Leclercq N, Azzouzi A-R, Soulié M, Patard J-J. Nephron-sparing surgery for renal tumors measuring more than 7 cm: morbidity, and functional and oncological outcomes. *Clin Genitourin Cancer.* 2014 Feb;12(1):e19–27.

33. Colin P, Ghoneim TP, Nison L, Seisen T, Lechevallier E, Cathelineau X, Ouzzane A, Zerbib M, Long J-A, Ruffion A, Crouzet S, Cussenot O, Audouin M, Irani J, Gardic S, Gres P, **Audenet F**, Roumigué M, Valeri A, Rouprêt M. Risk stratification of metastatic recurrence in invasive upper urinary tract carcinoma after radical nephroureterectomy without lymphadenectomy. *World J Urol.* 2014 Apr;32(2):507–12.

34. **Audenet F**, Audouin M, Drouin SJ, Comperat E, Mozer P, Chartier-Kastler E, Méjean A, Cussenot O, Shariat SF, Rouprêt M. Charlson score as a single pertinent criterion to select candidates for active surveillance among patients with small renal masses. *World J Urol.* 2014 Apr;32(2):513–8.

35. Forgues A, Rozet F, **Audenet F**, Ouzzane A, Sanchez-Salas R, Barret E, Galiano M, Prapotnich D, Cathelineau X. Oncologic outcomes after minimally invasive radical prostatectomy in patients with seminal vesicle invasion (pT3b) without adjuvant therapy. *World J Urol.* 2014 Apr;32(2):519–24.

36. Hollande C, Colin P, la Motte Rouge de T, **Audenet F**, Yates DR, Phe V, Ouzzane A, Droupy S, Ruffion A, La Taille De A, Guy L, Cussenot O, Rozet F, Xylinas E, Zerbib M, Spano J-P, Khayat D, Bitker M-O, Rouprêt M, French Collaborative National Working-Group on UTUC. Hereditary-like urothelial carcinomas of the upper urinary tract benefit more from adjuvant cisplatin-based chemotherapy after radical nephroureterectomy than do sporadic tumours. *BJU Int.* 2014 Apr;113(4):574–80.

37. Rizk J, **Audenet F**, Brichart N, Capon G, Dariane C, Fiard G, Lebdaï S, Madec F-X, Maurin C, Sanson S, Tanchoux C, Thibault F, Murez T, Terrasa J-B, Terrier J-E. Place du Master 2 recherche dans la formation des jeunes urologues français : une étude de l'AFUF. *Prog Urol*. 2014 May;24(6):359–66.
38. Fiard G, Capon G, Rizk J, Maurin C, Dariane C, **Audenet F**, Tanchoux C, Brichart N, Lebdaï S, Sanson S, Madec F-X, Thibault F, Terrasa J-B, Murez T, Terrier J-E. Évaluation de l'utilisation de la simulation dans la formation des jeunes urologues français : une enquête de l'association française des urologues en formation (AFUF). *Prog Urol*. 2014 May;24(6):390–6.
39. Dariane C, Rizk J, Meyer F, **Audenet F**, Brichart N, Capon G, Fiard G, Lebdaï S, Madec F-X, Maurin C, Murez T, Sanson S, Tanchoux C, Terrasa J-B, Thibault F, Terrier J-E. État des lieux des rémunérations des gardes et astreintes d'urologie en France: une étude de l'AFUF. *Prog Urol*. 2014 Jun;24(7):456–62.
40. Celhay O, Brichart N, **Audenet F**, Capon G, Dariane C, Fiard G, Lebdaï S, Madec F-X, Maurin C, Sanson S, Rizk J, Tanchoux C, Thibault F, Terrasa J-B, Murez T, Terrier J-E. Accessibilité prévisible au post-internat d'urologie en France jusqu'en 2016: une mise à jour de l'AFUF. *Prog Urol*. 2014 Sep;24(10):658–64.
41. Ploussard G, Staerman F, Pierrelcin J, Larue S, Villers A, Ouzzane A, Bastide C, Gaschnard N, Buge F, Pfister C, Bonniol R, Rebillard X, Fadli S, Mottet N, Saint F, Saad R, Beauval J-B, Rouprêt M, **Audenet F**, Peyromaure M, Delongchamps NB, Vincendeau S, Fardoun T, Rigaud J, Soulié M, Salomon L, Committee of Cancerology (CCAFU) of the Association of French Urology (AFU). Clinical outcomes after salvage radiotherapy without androgen deprivation therapy in patients with persistently detectable PSA after radical prostatectomy: results from a national multicentre study. *World J Urol*. Springer Berlin Heidelberg; 2014 Oct;32(5):1331–8.
42. Correas J-M, Khairoune A, **Audenet F**, Tissier A, Timsit M, Méjean A, Hélénon O. IRM multiparamétrique et élastographie ultrasonore par ondes de cisaillement dans le diagnostic du cancer de prostate : performances relatives. *Prog Urol*. 2014 Nov;24(13):814–5.
43. Champy C, **Audenet F**, Timsit M-O, Ariane M, Le Guilchet, Hurel S, Fontaine E, Méjean A. La tumorectomie rénale remplit aussi bien les objectifs du « TRIFECTA » que la néphrectomie élargie lors de la prise en charge des carcinomes à cellules rénales pT3a de découverte fortuite. *Prog Urol*. 2014 Nov;24(13):824.
44. **Audenet F**, Khairoune A, Timsit M, Sadfi A, Hélénon O, Méjean A, Correas J-M. Complications urologiques après traitement percutané des tumeurs du rein. *Prog Urol*. 2014 Nov;24(13):825–6.
45. Beaugerie A, Verkarre V, Ariane M, **Audenet F**, Correas J-M, Vasiliu V, Richard S, Méjean A, Timsit M. Tumeurs du rein multiples sporadiques : quelle concordance histologique ? *Prog Urol*. 2014 Nov;24(13):834.
46. Beaugerie A, Verkarre V, Ariane M, **Audenet F**, Correas J-M, Vasiliu V, Richard S, Méjean A, Timsit M. Dépistage oncogénétique dans les tumeurs du rein multiples : quelle pratique ? Quels résultats ? *Prog Urol*. 2014 Nov;24(13):834–5.
47. Celhay O, Brichart N, **Audenet F**, Capon G, Dariane C, Fiard G, Lebdaï S, Madec F, Maurin C, Sanson S, Rizk J, Tanchoux C, Thibault F, Terrasa J, Murez T, Terrier J. Accessibilité prévisible au post-internat d'urologie jusqu'en 2016. *Prog Urol*. 2014 Nov;24(13):836.
48. Mandron E, **Audenet F**, Dandrea M, Timsit M, Méjean A. Une nouvelle approche pour l'adénomectomie laparoscopique : la voie trans-cervicale. *Prog Urol*. 2014 Nov;24(13):899.
49. **Audenet F**, Rouprêt M, Houédé N, Colin P. Traitements non chirurgicaux des tumeurs de la voie excrétrice supérieure: état-de-l'art pour le rapport annuel de l'Association française d'urologie. *Prog Urol*. 2014 Nov;24(15):1030–40.
50. Uzan J, Cornou C, Bensaid C, **Audenet F**, Ngô C, Bats A-S, Lecuru F. Robot-Assisted Laparoscopic Partial Colectomy and Intracorporeal Ileal Conduit Urinary Diversion (Bricker) for Cervical Adenocarcinoma Recurrence. *Case Rep Obstet Gynecol*. 2015;2015(1):241094–4.
51. Hurel S, Rouprêt M, Seisen T, Comperat E, Phe V, Droupy S, **Audenet F**, Pignot G, Cathelineau X, Guy L, Cussenot O, Ouzzane A, Bozzini G, Nison L, Ruffion A, Colin P. Influence of preoperative factors on the oncologic outcome for upper urinary tract urothelial carcinoma after radical nephroureterectomy. *World J Urol*. 2015 Mar;33(3):335–41.
52. Mathieu R, Pignot G, Ingles A, Crepel M, Bigot P, Bernhard J-C, Joly F, Guy L, Ravaud A, Azzouzi A-R, Gravis G, Chevreau C, Zini L, Lang H, Pfister C, Lechevallier E, Faïs P-O, Berger J, Vayleux B, Rouprêt M, **Audenet F**, Descazeaud A, Rigaud J, Machiels J-P, Staehler M, Salomon L, Ferriere J-M, Kleindlauss F, Bensalah K, Patard J-J. Nephrectomy improves overall survival in patients with metastatic renal cell carcinoma in cases of favorable MSKCC or ECOG prognostic features. *Urol Oncol*. 2015 Aug;33(8):339.e9–15.
53. Oderda M, **Audenet F**, Briganti A, Brown M, De Marco V, Gan M, Janssen M, Navarro R, Sanchez-Salas R, Wit E. Re: Alessandro Volpe, Kamran Ahmed, Prokar Dasgupta, et al. Pilot Validation Study of the European Association of Urology Robotic Training Curriculum. *Eur Urol* 2015;68:292–9. *Eur Urol*. 2015 Aug;68(2):e29–e30.
54. Batista da Costa J, **Audenet F**, Le Guilchet T, Hurel S, Beaugerie A, Fontaine E, Timsit M, Méjean A. Le score de Charlson est associé aux complications post-opératoires lors de la prise en charge chirurgicale des petites masses rénales. *Prog Urol*. 2015 Nov;25(13):745–6.
55. Wiedemann L, **Audenet F**, Le Guilchet T, Hurel S, Beaugerie A, Fontaine E, Timsit M, Méjean A. Particularités de la chirurgie pour tumeurs rénales chez les patients de moins de 40 ans. *Prog Urol*. 2015 Nov;25(13):799.
56. Le Guilchet T, **Audenet F**, Hurel S, Beaugerie A, Fontaine E, Terrier N, Timsit M-O, Méjean A. Traitement conservateur des fistules urinaires du haut appareil par sonde urétérale trans-vésico-pariétale mise en place par voie percutanée. *Prog Urol*. 2015 Nov;25(13):818.
57. De Saint Aubert N, Méjean A, Verkarre V, Fontaine E, Ariane M, **Audenet F**, Timsit M. Comparaison des résultats de la chirurgie conservatrice vs totale dans le traitement des carcinomes à cellules rénales classés cT2. *Prog Urol*. 2015 Nov;25(13):825–6.
58. Cholley I, Correas J-M, Sanchez S, Ariane M, Fontaine E, Thiounn N, Hurel S, Le Guilchet T, Champy C, **Audenet F**, Pietak M, Méjean A, Timsit M-O. Comparaison de la chirurgie conservatrice vs ablation par radiofréquence pour le

- traitement du carcinome à cellules rénales après 75 ans. *Prog Urol.* 2015 Nov;25(13):827-8.
59. Pouessel D, Chevret S, Rolland F, Gravis G, Geoffrois L, Roubaud G, Terrisse S, Boyle H, Chevreau C, Dauba J, Moriceau G, Alexandre I, Deplanque G, Chapelle A, Vauleon E, Colau A, **Audenet F**, Grellety T, Culine S. Standard or accelerated methotrexate, vinblastine, doxorubicin and cisplatin as neoadjuvant chemotherapy for locally advanced urothelial bladder cancer: Does dose intensity matter? *Eur J Cancer.* 2016 Feb;54:69–74.
  60. Ingels A, Barret E, Sanchez-Salas R, Galiano M, Rozet F, Lenoir S, Weber N, **Audenet F**, Cathelineau X. Percutaneous Renal Biopsies for Small Renal Masses: Complex Tumors on Nephrometry Should Be the First Targets. *Clin Genitourin Cancer.* 2016 Oct;14(5):e457–62.
  61. Le Guilchet T, **Audenet F**, Hurel S, Beaugerie A, Fontaine E, Terrier N, Timsit MO, Méjean A. Traitement conservateur des fistules urinaires du haut appareil par sonde urétérale trans-vésico-pariétale. *Prog Urol.* 2016 Mar;26(3):152–8.
  62. Lebdaï S, Basset V, Branchereau J, La Taille De A, Flamand V, Lebrete T, Murez T, Neuzillet Y, Ploussard G, **Audenet F**. What do we know about treatment sequencing of abiraterone, enzalutamide, and chemotherapy in metastatic castration-resistant prostate cancer? *World J Urol.* 2016 May;34(5):617–24.
  63. Beaugerie A, Verkarre V, **Audenet F**, Le Guilchet T, Hurel S, Richard S, Correas J-M, Fontaine E, Méjean A, Timsit MO. Dépistage oncogénétique des patients atteints de tumeurs rénales multiples : quelle pratique pour quels résultats ? *Prog Urol.* 2016 Jun;26(8):442–9.
  64. Dariane C, Le Guilchet T, Hurel S, **Audenet F**, Beaugerie A, Badoual C, Tordjman J, Clément K, Urien S, Pietak M, Fontaine E, Méjean A, Timsit M-O. Prospective assessment and histological analysis of adherent perinephric fat in partial nephrectomies. *Urol Oncol.* 2017 Feb;35(2):39.e9–39.e17. Gravis G, **Audenet F**, Irani J, Timsit M-O, Barthelemy P, Beuzeboc P, Fléchon A, Linassier C, Oudard S, Rebillard X, Richaud P, Rouprêt M, Thiery Vuillemin A, Vincendeau S, Albiges L, Rozet F. Chemotherapy in hormone-sensitive metastatic prostate cancer: Evidences and uncertainties from the literature. *Cancer Treat Rev.* 2017 Apr;55:211–7.
  65. Iyer G, **Audenet F**, Middha S, Carlo MI, Regazzi AM, Funt S, Al-Ahmadie H, Solit DB, Rosenberg JE, Bajorin DF. Mismatch repair (MMR) detection in urothelial carcinoma (UC) and correlation with immune checkpoint blockade (ICB) response. *J Clin Oncol.* 2017 May 30;35:15\_suppl:4511–4511.
  66. **Audenet F**, Retinger C, Chien C, Benfante NE, Bochner BH, Donat SM, Herr HW, Dalbagni G. Is restaging transurethral resection necessary in patients with non-muscle invasive bladder cancer and limited lamina propria invasion? *Urol Oncol.* 2017 Oct;35(10):603.e1-603.e5.
  67. **Audenet F**, Sfakianos JP. Psychosocial impact of penile carcinoma. *Transl Androl Urol.* 2017 Oct;6(5):874–8.
  68. **Audenet F**, Sfakianos JP. Evidence of Atypical Recurrences After Robot-Assisted Radical Cystectomy: A Comprehensive Review of the Literature. *Bladder Cancer.* 2017 Oct 27;3(4):231–6.
  69. **Audenet F**, Rozet F, Resche-Rigon M, Bernard R, Ingels A, Prapotnich D, Sanchez-Salas R, Galiano M, Barret E, Cathelineau X. Grade Group Underestimation in Prostate Biopsy: Predictive Factors and Outcomes in Candidates for Active Surveillance. *Clin Genitourin Cancer.* 2017 Dec;15(6):e907–13.
  70. Gury-Coupier L, **Audenet F**, Delavaud C, Timsit M-O, Mejean A. [Retrospective comparison of the reproducibility and the performances of R.E.N.A.L. score, 12 segments score and UPRCC score for the partial nephrectomy]. *Prog Urol.* 2017 Dec;27(16):1050–7.
  71. Donahu TF, Bagrodia A, **Audenet F**, Donoghue MTA, Cha EK, Sfakianos JP, Sperling D, Al-Ahmadie H, Clendenning M, Rosty C, Buchanan DD, Jenkins M, Hopper J, Winship I, Templeton AS, Walsh MF, Stadler ZK, Iyer G, Taylor B, Coleman J, Lindor NM, Solit DB, Bochner BH. Genomic Characterization of Upper-Tract Urothelial Carcinoma in Patients With Lynch Syndrome. *JCO Precis Oncol.* 2018;2018.
  72. **Audenet F**, Vertosick EA, Fine SW, Sjoberg DD, Vickers AJ, Reuter VE, Eastham JA, Scardino PT, Touijer KA. Biopsy Core Features are Poor Predictors of Adverse Pathology in Men with Grade Group 1 Prostate Cancer. *J Urol.* 2018;199(4):961–8.
  73. Isharwal S, Huang H, Nanjangud G, **Audenet F**, Chen Y-B, Gopalan A, Fine SW, Tickoo SK, Lee BH, Iyer G, Chadalavada K, Rosenberg JE, Bajorin DF, Herr HW, Donat SM, Dalbagni G, Bochner BH, Solit DB, Reuter VE, Al-Ahmadie HA. Intratumoral heterogeneity of ERBB2 amplification and HER2 expression in micropapillary urothelial carcinoma. *Hum Pathol.* 2018;77:63–9.
  74. Beaugerie A, **Audenet F**, Verkarre V, Delavaud C, Le Guilchet T, Hurel S, de Saint Aubert N, Correas J-M, Fontaine E, Richard S, Méjean A, Timsit M-O. Pathological heterogeneity in sporadic synchronous renal tumors: Is the histological concordance predictable? *Urol Oncol.* 2018 Jan;36(1):11.e7-11.e12.
  75. Cholley I, Correas JM, Masson-Lecomte A, Sanchez S, Champy C, Le Guilchet T, Ariane M, Hurel S, **Audenet F**, Thiounn N, Fontaine E, Mejean A, Timsit MO. [Comparison of operative and oncologic results between partial nephrectomy and radiofrequency ablation for treatment of renal tumors in patients older than 75]. *Prog Urol.* 2018 Jan;28(1):55–61.
  76. Bagrodia A, **Audenet F**, Pietzak EJ, Kim K, Murray KS, Cha EK, Sfakianos JP, Iyer G, Singla N, Arcila M, Bochner BH, Al-Ahmadie HA, Solit DB, Coleman JA. Genomic Profile of Urothelial Carcinoma of the Upper Tract from Ureteroscopic Biopsy: Feasibility and Validation Using Matched Radical Nephroureterectomy Specimens. *Eur Urol Focus.* 2018 Jan 30;
  77. **Audenet F**, Sfakianos JP. Dealing with perioperative antiplatelet treatment for transurethral resection of the bladder: primum non nocere. *Transl Androl Urol.* 2018 May;7(Suppl 2):S258–9.
  78. de Saint Aubert N, **Audenet F**, Mccaig F, Delavaud C, Verkarre V, Le Guilchet T, Dariane C, Pettenati C, Slaoui H, Mejean A, Timsit MO. Nephron sparing surgery in tumours greater than 7cm. *Prog Urol.* 2018 May;28(6):336–43.
  79. **Audenet F**, Attalla K, Sfakianos JP. The evolution of bladder cancer genomics: What have we learned and how can we use it? *Urol Oncol.* 2018 Jul;36(7):313–20.
  80. Alvim RG, **Audenet F**, Vertosick EA, Sjoberg DD, Touijer KA. Performance Prediction for Surgical Outcomes in Partial Nephrectomy Using Nephrometry Scores: A Comparison of Arterial Based Complexity (ABC), RENAL, and

- PADUA Systems. *European Urology Oncology*. 2018 Oct;1(5):428–34.
81. Nouhaud F-X, Bernhard J-C, Bigot P, Khene Z-E, **Audenet F**, Lang H, Bergerat S, Fraisse G, Grenier N, Cornelis F, Nedelcu C, Béjar S, Fromont-Hankard G, Allory Y, Lindner V, Verkarre V, Daniel L, Yacoub M, Correias J-M, Méjean A, Rioux-Leclercq N, Bensalah K. Contemporary assessment of the correlation between Bosniak classification and histological characteristics of surgically removed atypical renal cysts (UroCCR-12 study). *World J Urol*. 2018 Oct;36(10):1643–9.
  82. Pignot G, Houédé N, Roumiguié M, **Audenet F**, Brunelle S, Colin P, Compérat E, Larré S, Masson-Lecomte A, Neuzillet Y, Xylinas E, Méjean A, Rouprêt M, les membres du CCAFU Vessie. [ypT0N0 after neoadjuvant chemotherapy and cystectomy for muscle-invasive bladder cancer: Incidence and prognosis. A review from the Bladder group of the French Committee of Oncology]. *Prog Urol*. 2018 Oct;28(12):567–74.
  83. **Audenet F**, Farkas AM, Anastos H, Galsky MD, Bhardwaj N, Sfakianos JP. Immune phenotype of peripheral blood mononuclear cells in patients with high-risk non-muscle invasive bladder cancer. *World J Urol*. 2018 Nov;36(11):1741–8.
  84. **Audenet F**, Waingankar N, Ferket BS, Niglio SA, Marqueen KE, Sfakianos JP, Galsky MD. Effectiveness of Transurethral Resection plus Systemic Chemotherapy as Definitive Treatment for Muscle Invasive Bladder Cancer in Population Level Data. *J Urol*. 2018 Nov;200(5):996–1004.
  85. Marqueen KE, Waingankar N, Sfakianos JP, Mehrazin R, Niglio SA, **Audenet F**, Jia R, Mazumdar M, Ferket BS, Galsky MD. Early Mortality in Patients With Muscle-Invasive Bladder Cancer Undergoing Cystectomy in the United States. *JNCI Cancer Spectr*. 2018 Nov;2(4):pky075.
  86. Rouprêt M, Neuzillet Y, Pignot G, Compérat E, **Audenet F**, Houédé N, Larré S, Masson-Lecomte A, Colin P, Brunelle S, Xylinas E, Roumiguié M, Méjean A. Recommandations françaises du Comité de Cancérologie de l'AFU – Actualisation 2018–2020: tumeurs de la vessie. *Prog Urol*. 2018 Nov;28(12S):S46–78.
  87. Rouprêt M, Xylinas E, Colin P, Houédé N, Compérat E, **Audenet F**, Larré S, Masson-Lecomte A, Pignot G, Brunelle S, Roumiguié M, Neuzillet Y, Méjean A. [French ccAFU guidelines - Update 2018-2020: Upper tract urothelial carcinoma]. *Prog Urol*. 2018 Nov;28(12S):S32–45.
  88. Dominique I, Dariane C, Fourniol C, Le Guilchet T, Hurel S, Fontaine E, Mandron E, **Audenet F**, Mejean A, Timsit MO. Performing an early systematic Doppler-ultrasound fails to prevent hemorrhagic complications after complex partial nephrectomy. *Ther Adv Urol*. 2019;11:1–10.
  89. Pietzak EJ, Zabor EC, Bagrodia A, Armenia J, Hu W, Zehir A, Funt S, **Audenet F**, Barron D, Maamouri N, Li Q, Teo MY, Arcila ME, Berger MF, Schultz N, Dalbagni G, Herr HW, Bajorin DF, Rosenberg JE, Al-Ahmadie H, Bochner BH, Solit DB, Iyer G. Genomic Differences Between “Primary” and “Secondary” Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy. *Eur Urol*. 2019;75(2):231–9.
  90. Isharwal S, **Audenet F**, Drill E, Pietzak EJ, Iyer G, Ostrovnya I, Cha E, Donahue T, Arcila M, Jayakumaran G, Berger MF, Rosenberg JE, Bajorin DF, Coleman J, Dalbagni G, Reuter VE, Bochner BH, Solit DB, Al-Ahmadie HA. Prognostic Value of TERT Alterations, Mutational and Copy Number Alterations Burden in Urothelial Carcinoma. *Eur Urol Focus*. 2019;5(2):201–4.
  91. **Audenet F**, Sfakianos JP, Waingankar N, Ruel NH, Galsky MD, Yuh BE, Gin GE. A delay 8 weeks to neoadjuvant chemotherapy before radical cystectomy increases the risk of upstaging. *Urol Oncol*. 2019 Feb;37(2):116–22.
  92. **Audenet F**, Isharwal S, Cha EK, Donoghue MTA, Drill EN, Ostrovnya I, Pietzak EJ, Sfakianos JP, Bagrodia A, Murugan P, Dalbagni G, Donahue TF, Rosenberg JE, Bajorin DF, Arcila ME, Hechtman JF, Berger MF, Taylor BS, Al-Ahmadie H, Iyer G, Bochner BH, Coleman JA, Solit DB. Clonal Relatedness and Mutational Differences between Upper Tract and Bladder Urothelial Carcinoma. *Clin Cancer Res*. 2019 Feb 1;25(3):967–76.
  93. **Audenet F**, Attalla K, Giordano M, Pfail J, Lubin MA, Waingankar N, Gainsburg D, Badani KK, Sim A, Sfakianos JP. Prospective implementation of a nonopioid protocol for patients undergoing robot-assisted radical cystectomy with extracorporeal urinary diversion. *Urol Oncol*. 2019 May;37(5):300.e17-300.e23.
  94. Waingankar N, Jia R, Marqueen KE, **Audenet F**, Sfakianos JP, Mehrazin R, Ferket BS, Mazumdar M, Galsky MD. The impact of pathologic response to neoadjuvant chemotherapy on conditional survival among patients with muscle-invasive bladder cancer. *Urol Oncol*. 2019 May 18;
  95. Grinholtz D, Méjean A, **Audenet F**. Fraley's Syndrome: A Rare Cause of Obstruction of the Collecting System. *Urology*. 2019 Aug 1.